Amgen, AstraZeneca bolster their case for breakthrough asthma program as FDA considers taking up a review
Just a few days after submitting a BLA for their highly-touted asthma program, Amgen and AstraZeneca released new data they hope will continue to strengthen their FDA pitch.
The companies released further detailed Phase III results for tezepelumab early Thursday morning, and published the full dataset in the New England Journal of Medicine. Tezepelumab plus standard of care “demonstrated superiority” across the primary and all key secondary endpoints compared to the standard of care alone, they said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.